Prochlorperazine transmucosal - Reckitt Benckiser

Drug Profile

Prochlorperazine transmucosal - Reckitt Benckiser

Alternative Names: Emezine

Latest Information Update: 08 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Reckitt Benckiser
  • Class Antiemetics; Antipsychotics; Phenothiazines; Piperazines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Nausea and vomiting

Most Recent Events

  • 31 Dec 2008 Discontinued - Preregistration for Nausea and vomiting in USA (Transmucosal)
  • 28 Feb 2006 BioDelivery Sciences International has received a non-approvable letter from the FDA for Emezine in Nause and vomiting
  • 02 May 2005 Preregistration for Nausea and vomiting in USA (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top